Quince Therapeutics (QNCX) Preferred Stock Liabilities (2018 - 2019)
Quince Therapeutics (QNCX) posted quarterly Preferred Stock Liabilities of $87.0 million for Q1 2019, up 406.23% year-over-year from $17.2 million in Q1 2018, and little changed quarter-over-quarter from $86.9 million in Q4 2018.
Quince Therapeutics (QNCX) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Quince Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $87.0 million for Q1 2019.
- In Q1 2019, Preferred Stock Liabilities rose 406.23% year-over-year to $87.0 million; the TTM figure through Mar 2019 stood at $87.0 million (up 406.23% YoY), while the FY2018 annual figure was $86.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2019 stood at $87.0 million, roughly flat from $86.9 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $87.0 million in Q1 2019, with the low at $17.2 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 86.96 Mn |
| Dec 31, 2018 | 86.87 Mn |
| Sep 30, 2018 | 17.18 Mn |
| Jun 30, 2018 | 17.18 Mn |
| Mar 31, 2018 | 17.18 Mn |